A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption ...

GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The company's ...

(RTTNews) - Glucotrack, Inc. (GCTK), Wednesday, announced the results from its first-in-human trial of its continuous blood glucose monitoring or CBGM system, which will be presented at the 2025 ...

Glucotrack, Inc. announced that it will present safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system at the 2025 International ...

people with diabetes announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring, CBGM, system will be presented at the 2025 ...

The NovoPen Echo smart insulin pen now works with Dexcom CGM. [Image from Novo Nordisk] Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous ...